Background-The aim of this analysis was to determine the long-term prognostic value of lower serum chloride in patients with stable chronic heart failure. Electrolyte abnormalities are prevalent in patients with chronic heart failure. Little is known regarding the prognostic implications of lower serum chloride. Methods and Results-Serum chloride was measured in 1673 consecutively consented stable patients with a history of heart failure undergoing elective diagnostic coronary angiography. All patients were followed for 5-year all-cause mortality, and survival models were adjusted for variables that confounded the chloride-risk relationship. The average chloride level was 102±4 mEq/L. Over 6772 person-years of follow-up, there were 547 deaths. Lower chloride (per standard deviation decrease) was associated with a higher adjusted risk of mortality (hazard ratio 1.29, 95% confidence interval 1.12-1.49; P<0.001). Chloride levels net-reclassified risk in 10.4% (P=0.03) when added to a multivariable model (with a resultant C-statistic of 0.70), in which sodium levels were not prognostic (P=0.30). In comparison to those with above first quartile chloride (≥101 mEq/L) and sodium (≥138 meq/L), subjects with first quartile chloride had a higher adjusted mortality risk, whether they had first quartile sodium (hazard ratio 1.35, 95% confidence interval 1.08-1.69; P=0.008) or higher (hazard ratio 1.43, 95% confidence interval 1.12-1.85; P=0.005). However, subjects with first quartile sodium but above first quartile chloride had no association with mortality (P=0.67). Conclusions-Lower serum chloride levels are independently and incrementally associated with increased mortality risk in patients with chronic heart failure. A better understanding of the biological role of serum chloride is warranted.
S erum electrolyte abnormalities are common in patients with chronic heart failure, although their underlying causes are often multifactorial. Maladaptive neurohormonal responses can lead to dysregulation of arginine vasopressinmediated free water absorption and thirst activation. [1] [2] [3] As a result, the plasma concentration of sodium and chloride decreases. Sodium and chloride can also be lowered by chronic loop and thiazide diuretic use, which are often necessary for maintenance of euvolemia in patients with chronic heart failure. 4 Indeed, diuretics inhibit the electrolyte reabsorption in the thick ascending limb of Henle's loop and the distal convoluted tubules. 5, 6 As diuretics limit the kidney's ability to excrete maximally dilute urine through renal sodium and chloride wasting, their chronic use may lead to a state of electrolyte depletion. 7 
See Clinical Perspective
A low serum sodium level (hyponatremia) is a well-established adverse prognostic marker in patients with chronic heart failure. 8 However, the pharmacological manipulation of sodium levels in patients with heart failure has yet to demonstrate consistent effects on long-term outcomes. 9 Although similar mechanisms that lower sodium may also lower chloride levels, lower chloride levels may represent a broader homeostatic imbalance. Chloride plays a role in acid-base homeostasis, contributes to maintenance of urine and plasma electroneutrality, and may even effect neurohormonal activation. [10] [11] [12] Despite this broad biological role, very little is known regarding the prognostic implications of low serum chloride in patients with chronic heart failure. Therefore, the aim of this analysis is to determine the long-term prognostic value of lower serum chloride levels, especially as they relate to lower sodium levels, in patients with chronic, stable heart failure. Chloride Homeostasis in Heart Failure coronary angiography from 2001 to 2006. Detailed medical histories were obtained on all subjects upon enrollment. Blood samples were collected at the time of coronary angiography immediately after sheath placement, but before cardiac catheterization or any therapies were given (including anticoagulant medications). Patients with an acute coronary syndrome or a prior coronary revascularization within 30 days were excluded. Elective coronary angiography was performed for the following reasons: to rule out new or assess severity of established coronary artery disease (53%), preoperatively for cardiac surgery (21%), cardiomyopathy (14%), remote myocardial infarction (9%), preoperatively for noncardiac surgery (3%), orthotopic heart transplantation evaluation (1%), and miscellaneous (2%). A clinical history of chronic heart failure was determined by the treating clinicians and confirmed by trained research personnel who enrolled patients into GeneBank. All participants gave written informed consent as approved by the Cleveland Clinic Institutional Review Board.
Study Design and Data Definitions
An estimate of glomerular filtration rate (eGFR) was calculated by the Modification of Diet in Renal Disease equation. Electrolytes, renal indices, and B-type natriuretic peptide (BNP) were measured on the Abbot Architect platform (Abbott Laboratories, Abbott Park, IL), and red cell distribution width (RDW) was measured by the Advia 120 hematoanalyzer (Siemens Healthcare Diagnostics, Tarrytown, NY), all by a central core laboratory. Self-reported functional status was measured by the Duke Activity Status Index (DASI) Questionnaire, which the study participants completed at the time of enrollment. The DASI is a validated instrument for both functional status and prognosis in chronic heart failure. 13, 14 Lower DASI scores are associated with a worse prognosis. Left ventricular ejection fraction (LVEF) was determined via transthoracic echocardiography by Simpson's method as part of routine clinical care and in accordance with the American Society of Echocardiography guidelines. 15 Echocardiographic data and preangiography electrolyte levels (including chloride) were abstracted via chart review of the electronic medical record at the time of enrollment. Adjudicated outcomes were prospectively collected over the 5 years following enrollment. Death was validated by querying the Social Security Death Index.
Statistical Analysis
Continuous variables are presented as median (interquartile range) and categorical variables as percentages. Skewed variables were natural log-transformed as appropriate. The cohort was split into quartiles of serum chloride and quartiles of serum sodium levels. There was additional grouping for subjects in the first quartiles of both chloride and sodium, the first quartile of chloride only, the first quartile of sodium only, and those that were in neither. The Jonckheere-Terpstra or Cochrane-Armitage tests were used to determine trends for baseline characteristics across increasing quartiles of chloride. A backwards selection linear regression algorithm was used from the baseline characteristics to determine independent correlates of serum chloride. The significance level for variable removal was P≥0.10 and for variable addition was P≥0.05. Mortality curves for chloride quartiles were generated via the Kaplan-Meier method. Cumulative mortality rates were compared by log-rank analysis. After observing no trends with time for the Schoenfeld residuals, the association of chloride and 5-year mortality was performed via a Cox-proportional hazards model. In a separate survival analysis clarifying the risk relationship of low chloride level to low sodium level concordance or discordance, a categorical variable identifying the first quartile of chloride with or without first quartile of sodium was created. The multivariable model included covariates that were selected a priori either because of their prognostic relevance or their potential to confound the chloride-risk relationship. These included age, sex, systolic blood pressure, diabetes mellitus, LVEF, angiotensin converting enzyme inhibitor or angiotensin II receptor blocker use, beta-blocker use, loop diuretic use, and DASI score, as well as serum sodium, serum bicarbonate, and eGFR. Additional adjustments were made for a subset with both measured Values expressed as either median (interquartile range) or (%). ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide (N=811); COPD, chronic obstructive pulmonary disease; DASI, Duke Activity Status Index; eGFR, estimated glomerular filtration rate; and RDW, red cell distribution width (N=1495).
*P value from Jonckheere-Terpstra or Cochrane-Armitage trend tests. Chloride Homeostasis in Heart Failure BNP and RDW levels. Subgroups were divided according to loop diuretic use, diabetes mellitus, sex, coronary artery disease, heart failure with preserved (LVEF ≥40%) or reduced LVEF (LVEF <40%), chronic obstructive pulmonary disease, and eGFR< or ≥60 mL/min per 1.73 m2. The discrimination (C-statistic) of the impact of chloride levels on mortality was determined as previously described. 16 Category-free net-reclassification indices and integrated discrimination improvement were calculated for the addition of chloride to the multivariable model. 17 Fractional polynomials were plotted to show the continuous association of chloride with mortality. Double-sided P values <0.05 were considered statistically significant. Statistical analyses were performed using Stata 13.1 software (StataCorp LP, College Station, TX).
Results

Baseline Characteristics
In our study cohort (see Figure I in the Data Supplement for the consort diagram), serum chloride levels were normally distributed (mean 102±4 mEq/L; median 103 mEq/L [interquartile ranges 101-104 mEq/L]). The full range of chloride was 89 to 115 mEq/L. There were 231 subjects (13.6%) with Cl<98 mEq/L and 101 subjects (5.9%) with Cl>107 mEq/L. Baseline characteristics across increasing chloride quartiles are shown in Table 1 
Chloride and 5-Year Mortality
There were 1664 (99%) participants followed for 5-year allcause mortality. In this group, there were 547 (33%) deaths over 6772 person-years of follow-up. Kaplan-Meier estimates of cumulative mortality are shown in Figure 1 Figure 2 ). After additional adjustment for natural log-transformed BNP and RDW levels (deaths, n/N=217/713), every standard deviation decrement in chloride remained associated with an increased risk of 5-year mortality (HR 1.26, 95% CI 1.03-1.55; P=0.03 ). Within the model, standard deviation (3.3 mEq/L) decrements in sodium were not associated with mortality (P=0.30), despite the fact that lower sodium quartiles and sodium levels within the model, but without adjustment for chloride, were associated with higher 5-year mortality risk (see Figure II and III in the Data Supplement). Within the multivariable model, there was no interaction between sodium and chloride (P=0.15) or between bicarbonate and chloride (P=0.3). This relationship is shown in Figure 3 . Although there was little improvement in discrimination when chloride was added to the multivariable model (C-statistic: 0.70, 95% CI 0.68-0.72 versus 0.71, 95% CI 0.69-0.73), it reclassified risk in 10% of the cohort (net-reclassification indices 10.4%; P=0.03 and integrated discrimination improvement 0.3%; P=0.03). In a sensitivity analysis substituting natural log-transformed blood urea nitrogen (which was available in a subset, deaths n/N=231/794) for eGFR in the multivariable model, the association of decreasing chloride and mortality was similar (HR 1.32, 95% CI 1.08-1.62; P=0.008). Further, the association of chloride and mortality was also relatively unchanged with the addition of chronic obstructive pulmonary disease into the model (HR 1.30, 95% CI 1.13-1.50; P<0.001).
Kaplan-Meier estimates for 5-year mortality stratified by whether subjects were classified by the first quartiles of chloride and sodium are shown in Figure IV in the Data Supplement. Cumulative mortality was higher for subjects in the first chloride quartile, regardless of whether they were in the first sodium quartile (log-rank, χ 2 32.5; P<0.001). Subjects with chloride levels in first quartile had a significant adjusted mortality risk if they also had sodium levels in the first quartile (HR 1.35, 95% CI 1.08-1.69; P=0.008) or higher (HR 1.43, 95% CI 1.12-1.85; P=0.005; Table 3 ). However, subjects with chloride levels higher than the first quartile but with sodium levels in the first quartile, the adjusted mortality risk was not significant (P=0.67). Subgroup analyses revealed that lower chloride levels had relatively consistent risk of mortality across dichotomized subgroups of loop diuretic use, sex, diabetes mellitus, coronary artery disease, heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, chronic obstructive pulmonary disease, or eGFR < or ≥60 mL/min per 1.73m2 (Figure 4 ). Of these, only diuretic usage significantly interacted with the chloride-risk association (P=0.02).
Discussion
Our group has recently described the incremental prognostic role of serum chloride in the setting of decompensated heart failure receiving diuretic therapy that is above and beyond serum sodium levels. 18 Herein, we now report several key observations regarding the prognostic importance of electrolyte homeostasis in a large cohort of patients with chronic stable heart failure. First, serum chloride levels were strongly correlated to functional status (DASI Score), sodium, blood urea nitrogen, and loop diuretic use, whereas they were not closely correlated with more traditional markers of heart failure severity, such as LVEF and BNP. This suggests an extracardiac link between abnormal chloride homeostasis with functional impairment, renal function, and decongestive therapies. Second, lower chloride was independently and incrementally associated with higher mortality even in the chronic setting, despite multivariable risk adjustment for other electrolytes, including sodium, cardio-renal biomarkers, selfreported functional status, and medication use. These findings reveal that serum chloride levels may carry important prognostic information in patients across the spectrum of heart failure and highlight the need to better understand the potential benefits of strategies (especially for long-term diuretic strategies) that can preserve electrolyte homeostasis.
Our findings point to an association between chloride homeostasis and disease progression in heart failure, whereby clinical severity may be associated with uncontrolled chloride dilution and depletion. This may be potentiated by several maladaptive mechanisms. First, neurohormonal activation and acid-base changes in chronic heart failure modulate chloride levels. For example, in combination with increased thirst, 19 patients with heart failure have increased arginine vasopressin secretion, which in a mechanistically similar way to hyponatremia causes a dilutional hypochloremia. [1] [2] [3] Second, loop or thiazide diuretics inhibit chloride resorption, leading to a depletional hypochloremia. 5, 6, 20 Although the biological role of chloride is not well understood, these results highlight the clinical importance of small perturbations in chloride level, which may not be markedly abnormal. In addition, loop diuretic use did modify the risk of chloride levels, which supports the hypothesis that pharmacological effects on chloride levels may have prognostic implications.
In contrast to sodium, chloride levels may represent other adversely prognostic homeostatic perturbations in heart failure. Extensive literature from murine models has demonstrated that chloride (and not sodium) in the renal tubular fluid suppresses plasma renin activity after resorption in the thick ascending limb and by direct action on the macular densa. 11, 12 This mechanism can be suppressed with chronic loop diuretic use which blocks chloride resorption in the thick ascending limb and, over time, leads to excessive chloride loss, translating into hypochloremia. Whether depleted serum chloride levels result in increased plasma renin activity in humans with chronic heart failure remains unproven. Interestingly, recent genetic investigations into determinants of heart failure risk have pointed to loss-of-function gene variant in the CLCNKA chloride channel which affects cardiorenal interactions through salt sensitivity. 21 The findings of the current study further support the prognostic relevance of lower chloride. Also in a retrospective analysis of the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program, it was observed that serum chloride among other candidate variables had the strongest association with long-term mortality. 22 Intriguingly, the strong inverse relationship found in this study between serum chloride levels and prognosis remained The risk-adjusted probability of 5-year mortality of various chloride levels for a given sodium level. Multivariable adjustment for bicarbonate, estimated glomerular filtration rate, 10-year increase in age, systolic blood pressure, male sex, diabetes mellitus, ejection fraction, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) use, beta-blocker use, loop diuretic use, and 5-point decrease in Duke Activity Status Index (DASI) score. Chloride Homeostasis in Heart Failure after correction for serum sodium levels, which are a wellestablished prognostic markers in patients with chronic heart failure. 8, 23 Moreover, the prognostic value of serum sodium was markedly diminished within the multivariable model for mortality that included chloride levels. This finding may have broad implications for risk assignment in heart failure populations. Sodium levels are key components of many well-known chronic heart failure prognostic models 24 and are one of the most commonly used and strongest correlates of death and heart failure hospitalizations in heart failure populations. 25, 26 Importantly, analysis of chloride was absent in these models. As the current findings suggest, chloride levels may have confounded the relationship between sodium and risk, and chloride may further improve risk stratification. Indeed, lower chloride levels, especially when lower relative to sodium levels, may be indicative of a state of electrolyte depletion which can be characterized by a large difference in sodium level relative to chloride level. 10 As more chloride is excreted into the urine, bicarbonate anions are reabsorbed to maintain electroneutrality, which, in turn, provoke alkalosis. The observation that subjects with low chloride, but not low sodium, drives mortality risk supports the importance of identifying an electrolytedeplete phenotype. Further, making the distinction between dilutional and depletional hypochloremia is clinically relevant because it may have different therapeutic implications. 27 This analysis must be interpreted in the context of several limitations. We cannot exclude the presence of selection bias for undergoing diagnostic coronary angiography and treatment for chronic heart failure at a tertiary referral center. However, this cohort was relatively representative of a contemporary cohort with chronic heart failure with elevated BNP levels and a majority on beta-blocker or angiotensin converting enzyme inhibitor or angiotensin II receptor blocker therapies. Because chloride levels were only measured at one point in time, the prognostic impact of changing chloride levels could not be assessed. However, even small differences in a single chloride concentration measurement had noticeably higher mortality (Figure 1 ), supporting the strong prognostic value of this electrolyte. Diuretic dosage was not collected, urine electrolytes were not measured, and there were no data collected regarding physical examination findings and patient-level decision making. However, direct pharmacological manipulation of chloride levels in patients with chronic heart failure is not commonplace. There were also no formal volume status assessments, which limit the assessment of chloride distribution within the body. However, this is essential to understanding the mechanistic role chloride plays in the interstitial and intravascular spaces and should be the subject of future study. New York Heart Association Functional status was not prospectively collected in this cohort. Instead, the DASI was used, which is a validated, highly prognostic tool which yields a continuum of functional status assessment in patients with heart failure. 13, 14, 28 There have been no direct conversions between New York Heart Association class and the DASI. However, in a prospective cohort of heart failure patients who were clinically , and for all other subgroups, the P interaction >0.05. CAD indicates coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HFpEF, heart failure with preserved ejection fraction; and HFrEF, heart failure with reduced ejection fraction. Chloride Homeostasis in Heart Failure stabilized, those with an adverse 9-month prognosis had both a higher DASI (16±12) and New York Heart Association Class (2.8±1.1) than those without (DASI 25±17 and New York Heart Association Class 2.3±0.9).
14 Although heart failure hospitalizations were not adjudicated, the large number of outcomes with minimal loss to follow-up uniquely powers this analysis to determine the prognostic role of chloride in the setting of other strong prognostic variables.
Conclusions
Despite a relatively low prevalence of hyponatremia and hypochloremia in our cohort of patients with chronic stable heart failure, we observed that lower serum chloride level was associated with a higher 5-year mortality risk independent of renal function, self-reported functional status, medication use, loop diuretic use (and in a subset, independent of BNP and RDW). The adverse prognostic role of lower sodium levels was diminished in comparison. These findings highlight the need to describe the pathological underpinnings driving lower chloride in heart failure and explore therapies that preserve chloride homeostasis.
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